99mTc-Mesalamine as potential agent for diagnosis and monitoring of ulcerative colitis: labelling, characterisation and biological evaluation



Mesalamine was labelled with technetium-99m (99mTc) in high radiolabelling yield (~98.4 %), in vitro stability (~4 h) and in serum persistence (~24 h). Optimum labelling conditions were investigated. The structure of the complex was confirmed using in silico analysis. Molecular docking was performed to evaluate the complex binding to its biochemical target, the PPARγ receptor. Biodistribution and clearance studies were performed in normal and ulcerative colitis models in mice. The tracer’s localization was highest (~65.2 %) in microbial model compared to chemical model (~42.4 %) and normal mice (~22.1 %) at 60 min post injection. All data supported the usefulness of 99mTc-mesalamine as a radiotracer for ulcerative colitis.


Mesalamine 99mTc-Mesalamine complex Ulcerative colitis Diagnosis Biological evaluation PPARγ receptor 


  1. 1.
    Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos G (2005) Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11:1085–1091CrossRefGoogle Scholar
  2. 2.
    Sunkara S, Swanson G, Forsyth C, Keshavarzian C (2011) Chronic inflammation and malignancy in ulcerative colitis. Ulcers. doi: 10.1155/2011/714046 Google Scholar
  3. 3.
    Xiang J, Ouyang Q, Li G, Xiao N (2008) Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 14(1):53–57CrossRefGoogle Scholar
  4. 4.
    Neishaboori H, Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh S (2013) Calprotectin: a promising non-invasive tool for ulcerative colitis monitoring. Life Sci J 10(3):1356–1360Google Scholar
  5. 5.
    El-Kawy O, Ibrahim I, Farah K (2015) Technetium-99m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging. J Label Radiopharm. doi: 10.1002/jlcr.3306 Google Scholar
  6. 6.
    Dubuquoy L, Jansson E, Deeb S, Rakotobe S, Karoui M, Colombel J, Auwerx J, Pettersson S, Desreumaux P (2003) Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis. Gastroenterology 124:1265–1276CrossRefGoogle Scholar
  7. 7.
    Vamecq J, Latruffe N (2000) Peroxisome proliferator-activated receptors (PPARs) and their implications in diseases. Curr Opin Endocrinol Diabetes 7:8–18CrossRefGoogle Scholar
  8. 8.
    Kliewer S, Umesono K, Noonan D, Heyman R, Evans R (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358(6389):771–774CrossRefGoogle Scholar
  9. 9.
    Su C, Wen X, Bailey S, Jiang W, Rangwala S, Keilbaugh S, Flanigan A, Murthy S, Lazar M, Wu G (1999) novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Investig 104(4):383–389CrossRefGoogle Scholar
  10. 10.
    Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz M, Colombel J, Auwerx J (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator–activated receptor γ (PPARγ) heterodimer: a basis for new therapeutic strategies. J Exp Med 4:827–836CrossRefGoogle Scholar
  11. 11.
    Yang X, Wang L, Chen T, Hodge D, Resau J, DaSilva L, Farrar W (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275(7):4541–4544CrossRefGoogle Scholar
  12. 12.
    Marx N, Mach F, Sauty A, Leung J, Sarafi M, Ransohoff R, Libby P, Plutzky J, Luster AD (2000) A Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164(12):6503–6508CrossRefGoogle Scholar
  13. 13.
    Yamamoto-Furusho J, Jacintez-Cazares M, Furuzawa-Carballeda J, Fonseca-Camarillo G (2014) Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. Dis Markers. doi: 10.1155/2014/932530 Google Scholar
  14. 14.
    Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55(9):1341–1349CrossRefGoogle Scholar
  15. 15.
    Kruis W, Schreiber I, Theuer D, Brandes J, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U (2001) Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 49(6):783–789CrossRefGoogle Scholar
  16. 16.
    Desreumaux P, Ghosh S (2006) Mode of action and delivery of 5-aminosalicylic acid: new evidence. Aliment Pharmacol Ther 24(1):2–9CrossRefGoogle Scholar
  17. 17.
    Yang J, Chen C (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins 55:288–304CrossRefGoogle Scholar
  18. 18.
    Gampe J, Montana V, Lambert M, Miller A, Bledsoe K, Milburn M, Kliewer S, Willson T, Xu H (2000) Asymmetry in the PPARgamma/RXRalpha crystal structure the molecular basis heterodimerization among nuclear receptors. Mol Cell 5:545–555CrossRefGoogle Scholar
  19. 19.
    Shah S, Khan A, Khan M (2011) Radiosynthesis and biological evaluation of 99mTc(CO)3 sitafloxacin dithiocarbamate complex: a promising Staphyloccus aureus infection radiotracer. J Radioanal Nucl Chem 288:131–136CrossRefGoogle Scholar
  20. 20.
    Wang X, Zhao L, Han T, Chen S, Wang J (2008) Protective effects of 2,3,5,4′-tetrahydroxystilbene-2-o-beta-d-glucoside, an active component of polygonum multiflorum thumb on experimental colitis in mice. Eur J Pharmacol 578:339–348CrossRefGoogle Scholar
  21. 21.
    Westin S, Kurokawa R, Nolte R, Wisely G, McInerney E, Rose D, Milburn M, Rosenfeld M, Glass C (1998) Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199–202CrossRefGoogle Scholar
  22. 22.
    Stretch G, Campbell B, Dwarakanath A, Yaqoob M, Stevenson A, Morris AI, Rhodes JM (1996) 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, osalazine or mesalazine. Aliment Pharmacol Ther 10:941–947CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2015

Authors and Affiliations

  1. 1.Labelled Compounds DepartmentAtomic Energy AuthorityCairoEgypt

Personalised recommendations